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Swallowing impairment (dysphagia) post-stroke results in poorer outcomes. Pharyngeal electrical stimulation (PES) is a potential
treatment for post-stroke dysphagia. In a post hoc analysis, we investigated PES using videofluoroscopy swallow studies (VFSS)
from the STEPS trial incorporating multiple measures of safety (penetration aspiration scale-PAS), speed and duration (timing),
and efficiency (clearance), as opposed to the original trial which only measured PAS scores. 81 randomised participants (PES
(N = 43) versus sham (N = 38)) were analysed at baseline and 2 weeks. Participants swallowed up to 6 × 5ml and 1 × 50ml of thin
liquid barium at 40% w/v, images at ≥25 fps. Based on PAS, the 5ml mode bolus (most frequently occurring PAS from 6 × 5ml)
and the worst 50ml bolus were chosen for further analysis. Eight timing measures were performed, including stage transition
duration (STD) and pharyngeal transit time (PTT). Clearance measures comprised oral and pharyngeal residue and swallows to
clear. Comparisons of change of scoring outcomes between PES and sham were done at 2 weeks. Wilcoxon Signed Ranks Test was
also used to evaluate longitudinal changes from both groups’ combined results at two weeks. Between-group analysis showed no
statistically significant differences. Issues with suboptimal image quality and frame rate acquisition affected final numbers. At two
weeks, both groups demonstrated a significant improvement in most safety scores (PAS) and STD, possibly due to spontaneous
recovery or a combination of spontaneous recovery and swallowing treatment and usual care. A nonsignificant trend for
improvement was seen in other timing measures, including PTT. This study, which conducted additional measurements of
kinematic and residue analysis on the STEPS data did not detect “missed” improvements in swallowing function that the PAS is
not designed to measure. However, more studies with greater numbers are required.
1. Introduction
Dysphagia is associated with poorer outcomes [1, 2]. Despite
this, there are few proven treatments for post-stroke (PSD)
dysphagia and a pressing need for more high-quality trials
in order to assess which specific interventions are effective
[3]. Swallowing is a highly complex bodily function compris-
ing multiple components of extremely precise, rapid, and
often overlapping events, which is frequently assessed using
the Penetration Aspiration Scale (PAS) [4]. However, the
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PAS is complicated by high intrasubject variability [5–7], a
lack of standardised analysis methods to apply to PAS scores
and variability in statistical methods used to analyse the cho-
sen scores [6, 8]. Furthermore, the PAS only measures one
aspect of swallowing, i.e., the direction of bolus flow, and
does not consider collective measures of speed and duration
(bolus timing) and efficiency (bolus clearance) [9]. Using mul-
tiple measures of swallowing may provide a more complete
measure of swallowing function [9, 10]. Pharyngeal electrical
stimulation (PES) is a potential treatment for PSD and has been
used in several published studies to date [7, 11–13]. The largest
of these was the Swallowing Treatment using Electrical Pharyn-
geal Stimulation Trial (STEPS) [7]. This trial only compared
swallowing safety using PAS. We therefore investigated the
effect of PES on multiple measures of both speed and duration
(timing) and efficiency (clearance) as well as safety (PAS) by
conducting a retrospective analysis on the STEPS data.
2. Materials and Methods
2.1. Participants and Videofluoroscopy Swallowing Studies.
Data from the STEPS trial was used to carry out the analysis
[7]. In brief, participants (stroke onset within 42 days) were
given up to 7 boli (comprising 6 × 5ml boli and 1 × 50ml
(cup drinking) bolus) of thin fluids at 40% wt/vol of either
Omnipaque 300, Visipaque 270, or Accupaque during a base-
line VFSS. If consecutive occurrences of aspiration were seen,
“stop” criteria were applied; hence, not all participants
received all 7 boli. Participants meeting the recruitment cri-
teria (any bolus with PAS >2) were then randomly assigned
to either PES or sham treatment, which was given for 3 con-
secutive days. A follow-up VFSS was conducted at weeks 2
and 12 according to the STEPS protocol. The primary out-
come was the reduction in the mean PAS score of all boli
between baseline and VFSS at 2 weeks. Eighteen hospital sites
participated in the STEPS study. In the current study,
participants who were randomised to the active (PES)
group or sham group and who had a baseline, and two-
week VFSS were included, as well as those with VFSS data
recorded at a frame rate of ≥25 fps. Files were viewed in
Quick Time 7 (Apple Inc, USA) using frame-by-frame
analysis. Data was analysed on several different measure-
ments, and these are summarised in supplementary table 1
(in the Supplementary Material) and detailed below.
2.2. PAS, Timing, and Clearance Measures. Every swallow
performed to clear each 6 × 5ml bolus (i.e., primary and sec-
ondary (clearing swallows)) was given a PAS score. The high-
est PAS score from each 5ml bolus was identified, resulting
in 6 PAS scores. Of these, the mode PAS, i.e., the PAS score
occurring most frequently across the 6 boli [6], was chosen
for further analysis. For the 50ml bolus, the worst PAS score
was chosen for analysis. Several timing measures were per-
formed on the 5ml mode bolus: global oral transit time
(gOTT) as defined by the author for this study, stage transi-
tion duration (STD) [14], initiation of laryngeal closure
(ILC) [10], laryngeal vestibule closure reaction time (LVCrt)
[15], laryngeal closure duration (LCD) [16], pharyngeal
response time (PRT) [16], pharyngeal transit time (PTT)
[17], and upper oesophageal sphincter duration (UOSD)
[17, 18]. For the mode 5ml bolus and the worst 50ml bolus,
the Modified Barium Swallowing Impairment Profile
(MBSImP) [19] was also used to score initiation of the pha-
ryngeal swallow (component 6). For both boli, clearance
measures comprising oral and pharyngeal residue (compo-
nents 5 and 16 of the MBSImP), and a number of swallows
to clear were also measured. Operational definitions of the
timing measures used in this study are listed in supplemen-
tary table 2. Timing and clearance measures were always
taken from the primary swallow (including those swallows
showing secondary aspiration). The mean PAS score across
all 5ml boli and the mean 50ml bolus was also calculated
for comparison.
2.3. Ethics. The study underpinning the data had national
ethics approvals and patients (or surrogates) had given
written informed consent. The trial was registered as
ISRCTN25681641.
2.4. Statistical Analysis. Baseline characteristics and baseline
VFSS measures of participants were determined using
descriptive statistics. The Chi-Square test and Fisher’s Exact
Probability Test (binary and ordinal variables) and Welch’s
T-Test (continuous variables) were used to test for significant
differences between the groups at baseline. The primary out-
come was safety, timing, and clearance measures of the 5ml
mode bolus, and the secondary outcome was the same mea-
sures for the worst 50ml bolus. The change score from base-
line to two weeks for each group (PES versus sham) was
calculated and compared using the Independent T-Test
(unequal variances assumed) for timing (continuous) mea-
sures and the Mann–Whitney U Test for clearance (ordinal)
measures. Wilcoxon Signed Ranks Test was used to compare
both groups’ combined results at two weeks to evaluate
longitudinal changes.
2.5. Reliability Testing. Details of reliability information for
the safety, timing, and clearance measures used in this study
have been submitted for publication.
3. Results
3.1. Participants and Videofluoroscopy Swallowing Studies.
From the original dataset, 126 (of 162) participants received
PES or sham and had both a VFSS completed at baseline
and 2 weeks. This group comprised the primary outcome
population in the STEPS study and was also used for the cur-
rent study. Further analysis revealed that 42 participants in
this group had VFSS data recorded at a frame rate <25 fps,
two files were missing, and one file was unanalysable. These
files were excluded from this study (the excluded group).
This resulted in a final total of 81 files (64.3%) from the 126
participants in the timings and clearance analysis for this
study (the included group). In this included group, 71 files
(88%) were recorded at a frame rate of 25 fps and 10 files
(12%) were recorded at 30 fps. Supplementary figure 1
details the breakdown of frame rates for all files (N = 126).
Table 1 details the baseline characteristics of the excluded
group (N = 45) versus the included group (N = 81). No
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significant differences were apparent between these groups at
baseline, except for ethnicity. Table 1 also details the baseline
characteristics of the included group (N = 81), according to
PES (N = 43) and sham (N = 38). At baseline, the sham
group was more dependant (modified Rankin Score) and
more disabled (Barthel Index). However, clinical dysphagia
severity (Dysphagia Severity Rating Scale) [20] and feeding
route were similar between the groups.
Fifteen hospital sites (supplementary figure 2) were
included in the study. Most sites contributed <10% of the
overall data whilst one site contributed 37% of data. A
significant amount of measures were unable to be
calculated due to poor imaging quality and on occasions,
reduced field of view. This affected the final numbers for
statistical analysis as calculating the change score required
data to be available from both baseline and two-week
Table 1: Baseline characteristics for participants in STEPS: excluded vs. included (N = 126); included (N = 81, PES vs. sham). Data are
number (%), median [interquartile range], or mean (standard deviation). Comparison by Chi-Square (Exact) Test/Fisher’s Exact Test
(binary/ordinal variables) or Welch’s T-Test (continuous variables).
N All Excluded Included p N PES Sham
Patients 126 45 81 81 43 38
Age, y 126 73.4 (11.4) 73.3 (11.8) 73.4 (11.2) 0.98 81 72.8 (10.0) 74.1 (12.5)
Sex, female (%) 126 49 (38.9) 15 (33.3) 34 (42.0) 0.45 81 21 (48.8) 13 (34.2)
Ethnicity, white (%) 126 108 (85.7) 43 (95.6) 65 (80.2) 0.031 81 39 (90.7) 36 (94.7)
Modified Rankin Scale (/6) 126 4.1 (1.0) 4.0 (1.1) 4.1 (1.0) 0.47 81 3.9 (1.0) 4.4 (0.9)
Barthel Index (/100) 126 28.9 (29.8) 31.4 (30.8) 27.4 (29.4) 0.48 81 33.8 (32.7) 20.1 (23.4)
Stroke 3 (6.7) 12 (14.8) 0.25 81 43 37
Previous (%) 126 15 (11.9) 9 (20.9) 3 (7.9)
Type, ischaemic (%) 110 96 (87.3) 32 (86.5) 64 (87.7) 1.00 73 33 (86.8) 31 (88.6)
Side of CT lesion (%) 123 0.25 80 43 37
Left 55 (44.7) 20 (46.5) 35 (43.8) 19 (44.2) 16 (43.2)
Right 50 (40.7) 14 (32.6) 36 (45.0) 18 (41.9) 18 (48.6)
No lesion 18 (14.6) 9 (20.9) 9 (11.3) 6 (14.0) 3 (8.1)
Syndrome (%) 126 0.31 81
TACS 35 (27.8) 13 (28.9) 22 (27.2) 11 (25.6) 11 (28.9)
PACS 49 (38.9) 14 (31.1) 35 (43.2) 21 (48.8) 14 (36.8)
Lacunar 41 (32.5) 17 (37.8) 24 (29.6) 11 (25.6) 13 (34.2)
POCS 1 (0.8) 1 (2.2) 0 (0) 0 (0) 0 (0)
Severity, NIHSS (/42) 126 10.1 (6.5) 9.5 (7.3) 10.4 (6.0) 0.48 81 10.1 (6.1) 10.8 (5.9)
Dysphasia, NIHSS (%) 126 44 (34.9) 13 (28.9) 31 (38.3) 0.33 81 17 (39.5) 14 (36.8)
Onset to randomisation (days) mean (SD) 126 16.2 (9.9) 15.2 (8.3) 16.8 (10.7) 0.33 81 15.4 (10.3) 18.4 (11.1)
Median [IQR] 14 [11] 15.0 [12] 14.0 [16] 15.5 [15] 13.0 [13]
DSRS (/12) 126 7.4 (3.7) 7.8 (3.7) 7.1 (3.7) 0.35 81 7.4 (4.0) 6.8 (3.2)
TOR-BSST, failed (%) 126 122 (96.8) 45 (100) 77 (95.1) 0.30 81 41 (95.3) 36 (94.7)
Feeding route (%) 126 0.14 81 43 38
Oral, normal diet 7 (5.6) 5 (11.1) 2 (2.5) 2 (4.7) 0 (0)
Oral, soft diet 36 (28.6) 9 (20.0) 27 (33.3) 13 (30.2) 14 (36.8)
Nasogastric 70 (55.6) 27 (60.0) 43 (53.1) 25 (58.1) 18 (47.4)
PEG 2 (1.6) 0 (0) 2 (2.5) 2 (4.7) 0 (0)
Other 11 (8.7) 4 (8.9) 7 (8.6) 1 (2.3) 6 (15.8)
Weight (kg) 126 73.0 (16.1) 74.1 (16.5) 72.4 (15.9) 0.58 81 71.5 (14.8) 73.4 (17.2)
Body mass index (kg/m2) 122 25.6 (4.9) 25.7 (4.9) 25.5 (4.9) 0.88 77 25.8 (4.3) 25.3 (5.5)
Mid-arm circumference (cm) 125 28.5 (3.6) 28.2 (3.4) 28.6 (3.7) 0.61 80 28.3 (3.4) 28.9 (4.0)
Albumin (g/L) 120 3.6 (0.6) 3.6 (0.6) 3.7 (0.5) 0.44 77 3.7 (0.6) 3.6 (0.5)
Chest infection (%) 126 5 (4.0) 3 (6.7) 2 (2.5) 0.35 81 1 (2.3) 1 (2.6)
CT: computed tomography; DSRS: dysphagia severity rating scale; ICH: intracerebral haemorrhage; NIHSS: National Institutes of Health Stroke Scale; PEG:
percutaneous endoscopic gastrostomy; TACS: total anterior circulation syndrome; PACS: partial anterior circulating syndrome; POCS: posterior
communicating syndrome; TOR-BSST: Toronto Bedside Swallowing Screening Test. PES group associated with lower mRS (P = 0:032) and higher Barthel
Index (P = 0:032).
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timepoints. In addition, as each component comprised two
measures at each timepoint (for example, STD comprised
measures for bolus head at ramus and hyoid onset), for a
dataset to be complete, four measures were required in total.
3.2. PAS, Timing, and Clearance Measures.When comparing
outcomes between the PES versus sham group, at baseline for
the modal bolus (Table 2), there were no significant differ-
ences except for LCD (P = 0:039) and number of secondary
swallows (P = 0:048). When comparing the change score at
two weeks (Table 3), there were no significant differences
between the groups for any measures. For the worst 50ml
bolus, no significant differences were seen between the
groups at baseline (Table 4) or for the two-week score change
for any measures (Table 5).
When comparing outcomes of both groups (supplemen-
tary figure 3) combined at baseline and two weeks (to assess
for longitudinal changes), significant improvements in
safety scores were seen in all PAS conditions (i.e., mode
5ml bolus, mean of 5ml boli, and worst 50ml bolus) with
the exception of the mean 50ml PAS. For measures of
timing (supplementary figure 4), the only measure of
speed which showed a significant improvement was STD
(Z = −2:058, P < 0:04). However, there was a nonsignificant
trend for improved scores for OTT, ILC, and PTT at two
weeks but not for LVCrt and PRT. Minimal changes in
duration measures (LCD and UOSD) were seen. Large
standard deviations were seen at baseline for some timing
measures due to the inclusion of a small number of extreme
outliers. However, this data was not omitted because it was
felt that these scores represent a minority of severe patients
that are seen in acute stroke, who do present with very slow
swallowing function. As such, this data contains important
information which should not be discarded [21]. In
addition, the statistical method used with this data,
Wilcoxon Signed Ranks Test, is an appropriate test to use
Table 2: VFSS measures at baseline for 5ml mode swallow. Data are number (%) or mean (SD); comparison by Chi-Square (Exact)
Test/Fisher’s Exact Test or Welch’s T-Test.
5ml measures-mode swallow N All PES Sham
PAS, modal bolus 72 4.4 (2.9) 4.3 (3.1) [38] 4.5 (2.6) [34]
PAS, mean all boli 72 4.5 (1.8) 4.4 (1.9) [38] 4.7 (1.7) [34]
OTT (ms) 40 2.14 (3.39) 2.65 (4.14) [25] 1.30 (1.16) [15]
SRT 62 2.07 (6.55) 2.32 (8.53) [33] 1.77 (3.20) [29]
ILC 56 2.55 (6.87) 2.91 (9.08) [29] 2.16 (3.29) [27]
LVC_rt 57 0.38 (0.15) 0.39 (0.17) [29] 0.38 (0.12) [28]
LCD 56 0.44 (0.21) 0.50 (0.25) [28] 0.39 (0.13) [28]∗
PRT 36 0.86 (0.12) 0.89 (0.13) [20] 0.82 (0.10) [16]
PTT 37 3.73 (8.36) 4.29 (10.88) [20] 3.06 (3.96) [17]
UOSD 38 0.62 (0.16) 0.65 (0.17) [20] 0.59 (0.13) [18]
Initiation of pharyngeal swallow (0-4) 69 37 32
Bolus head-ramus 10 (14.5) 5 (13.5) 5 (15.6)
Bolus head-valleculae 12 (17.4) 10 (27.0) 2 (6.3)
Bolus head-laryngeal surface 8 (11.6) 2 (5.4) 6 (18.8)
Bolus head-pyriforms 39 (56.5) 20 (54.1) 19 (59.4)
No visible initiation 0 (0) 0 (0) 0 (0)
Oral residue (0-4) 56 28 28
Complete clearance 0 (0) 0 (0) 0 (0)
Trace residue 12 (21.4) 9 (32.1) 3 (10.7)
Residue collection 42 (75.0) 18 (64.3) 24 (85.7)
Majority bolus remaining 1 (1.8) 1 (3.6) 0 (0)
Minimal/no clearance 1 (1.8) 0 (0) 1 (3.6)
Pharyngeal residue (0-4) 63 34 29
Complete clearance 4 (6.3) 3 (8.8) 1 (3.4)
Trace residue 19 (30.2) 11 (32.4) 8 (27.6)
Residue collection 39 (61.9) 19 (55.9) 20 (69.0)
Majority bolus remaining 0 (0) 0 (0) 0 (0)
Minimal/no clearance 1 (1.6) 1 (2.9) 0 (0)
No. of swallows to clear 5ml 72 1.1 (1.1) 1.3 (1.1) [38] 0.8 (1.0) [34]∗
LCD was shorter in the sham group (P = 0:039), and fewer clearing swallows were seen in the sham group (P = 0:048).
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with outliers. With this test, each value is ranked in order and
then the sums are ranked and hence extreme values do not
heavily influence the sum [21].
There were no significant changes for IPS or any clear-
ance measures; (supplementary figure 5) although, there
was a trend for less swallows at two weeks in the 50ml bolus.
4. Discussion
4.1. PAS, Timing, and Clearance Measures. This current
study only included imaging data from the original STEPS
trial at ≥25 fps. Our findings with regards to PA scores agree
with the overall conclusion from the original STEPS study
which also did not show a significant change between groups
for safety. Furthermore, this current study which conducted
additional temporal and clearance measures on this data
has not demonstrated any new or “undetected” significant
differences between the groups. In other acute stroke treat-
ment studies using PES, improvements in safety (PAS scores)
were seen in smaller studies [12, 13] but not in the larger
multicentre STEPS Trial from which a portion of the data
in the current study is taken from [7]. In chronic stroke
patients, improvements in PAS scores post-PES were seen
in one study [22]. Improvements in timing measures,
namely, STD and PTT, were reported in one previous study
in acute stroke patients, using PES [11], although a further
study also using PES in acute stroke patients reported no
improvements in these two measures or for OTT or LCD
[12]. With regard to clearance measures, no studies have
reported on the effects of PES using this component.
The significant improvement in PAS scores observed in
both groups at two weeks could have been due to spontaneous
recovery. Longitudinal observational studies at 1-month post-
onset [9] and up to a year [23], as well as treatment studies
[24] in acute and subacute stroke, have reported improved
PAS scores over time. These clinical findings correlate with
physiological evidence from TMS studies demonstrating
improved swallow function in many acute stroke patients with
Table 3: Comparison of PAS, timing, and clearance measures for 5ml mode swallow, by change score from baseline to two weeks, using
Independent Samples T-Test (continuous variables) and Mann–Whitney U Test (ordinal variables).






Difference (95% CI) P value
PAS, modal bolus 38 -1.45 (3.06) 33 -0.85 (2.54) -0.60 (-1.93, 0.73) 0.37
PAS, mean all boli 38 -0.99 (1.66) 34 -0.95 (1.58) -0.04 (-0.80, 0.72) 0.91
OTT 20 -0.64 (1.83) 9 -0.51 (1.37) -0.13 (-1.41, 1.14) 0.83
SRT 28 -1.98 (8.94) 27 -1.05 (3.39) -0.92 (-4.60, 2.76) 0.62
ILC 24 -2.04 (9.73) 24 -1.17 (3.55) -0.87 (-5.19, 3.45) 0.68
LVC_rt 25 -0.07 (0.15) 25 -0.01 (0.19) -0.07 (-0.17, 0.03) 0.18
LCD 22 0.04 (0.18)) 25 -0.00 (0.19) 0.04 (-0.07, 0.15) 0.43
PRT 15 0.01 (0.16) 9 0.01 (0.08) -0.00 (-0.10, 0.10) 0.97
PTT 15 -3.66 (12.12) 10 -1.49 (5.26) -2.17 (-9.55, 5.21) 0.55
UOSD 15 0.03 (0.15) 10 0.00 (0.09) 0.03 (-0.07, 0.13) 0.58
Initiation of pharyngeal swallow (0-4) 36 0 [2] 32 0 [1] -0.5 (-1,0) 0.52
Ramus 8 (22.2) 5 (15.6)
Valleculae 6 (16.7) 2 (6.3)
Laryngeal surface 5 (13.9) 3 (9.4)
Pyriforms 17 (47.2) 22 (68.8)
No visible initiation 0 (0.0)
Oral residue (0-4) 22 0 [0] 23 0 [0] -0.5 (-1,0) 0.64
Complete clearance 0 (0.0) 0 (0.0)
Trace residue 7 (31.8) 5 (21.7)
Residue collection 14 (63.6) 18 (78.3)
Majority bolus remaining 1 (4.5) 0 (0.0)
Minimal/no clearance 0 (0.0) 0.(0.0)
Pharyngeal residue (0-4) 31 0 [0] 29 0 [1] 0 (-1,0) 0.53
Complete clearance 2 (6.5) 0 (0.0)
Trace residue 11 (35.5) 14 (48.3)
Residue collection 18 (58.1) 15 (51.7)
Majority bolus remaining 0 (0.0) 0.(0.0)
Minimal/no clearance 0 (0.0) 0 (0.0)
No. of swallows to clear 5ml 38 0.11 (1.39) 33 0.12 (1.22) -0.02 (-0.63, 0.60) 0.96
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Table 4: VFSS measures at baseline for 50ml bolus (comparison by Chi-square/Fisher’s Exact Test or Welch’s T-Test (unpooled test).
50ml measures at baseline N All PES Sham
PAS, 50ml worst 49 6.7 (1.8) 6.6 (1.7) [25] 6.8 (2.0) [24]
PAS, 50ml mean 49 3.6 (1.9) 3.3 (1.8) [25] 3.9 (1.9) [24]
No. swallows to clear 49 7.8 (5.0) 8.0 (5.5) [25] 7.5 (4.6) [24]
Initiation of pharyngeal swallow 45 22 23
Bolus head-ramus 3 (6.7) 3 (13.6) 0 (0.0)
Bolus head-valleculae 4 (8.9) 2 (9.1) 2 (8.7)
Bolus head-laryngeal surface 5 (11.1) 3 (13.6) 2 (8.7)
Bolus head-pyriforms 33 (73.3) 14 (63.6) 19 (82.6)
No visible initiation 0 (0) 0 (0.0) 0 (0.0)
Oral residue (0-4) 40 22 18
Complete clearance 0 (0) 0 (0.0) 0 (0.0)
Trace residue 1 (2.5) 1 (4.5) 0 (0.0)
Residue collection 37 (92.5) 20 (90.9) 17 (94.4)
Majority bolus remaining 1 (2.5) 1 (4.5) 0 (0.0)
Minimal/no clearance 1 (2.5) 0 (0.0) 1 (5.6)
Pharyngeal residue (0-4) 43 23 20
Complete clearance 0 (0) 0 (0.0) 0 (0.0)
Trace residue 10 (23.3) 7 (30.4) 3 (15.0)
Residue collection 31 (72.1) 14 (60.9) 17 (85.0)
Majority bolus remaining 1 (2.3) 1 (4.3) 0 (0.0)
Minimal/no clearance 1 (2.3) 1 (4.3) 0 (0.0)
Table 5: Comparison of PAS, timing, and clearance measures for 50ml worst swallow, by change score from baseline to two weeks, using
Independent Samples T-Test (continuous variables) and Mann–Whitney U Test (ordinal variables).






Difference/95% (CI) P value
PAS, 50ml worst 24 -1.04 (2.73) 22 -0.95 (3.03) -0.09 (-1.81, 1.63) 0.92
PAS, 50ml mean 24 -0.42 (1.93) 22 -0.64 (1.59) 0.22 (-0.83, 1.27) 0.68
No. swallows to clear 24 -1.17 (4.30) 22 -1.27 (4.92) 0.11 (-2.65, 2.87) 0.94
Initiation of pharyngeal swallow (0-4) 21 20 0.58
Bolus head-ramus 4 (19.0) 1 (5.0)
Bolus head-valleculae 0 (0.0) 0 (0.0)
Bolus head-laryngeal surface 3 (14.3) 5 (25.0)
Bolus head-pyriforms 14 (66.7) 14 (70.0)
No visible initiation 0 (0.0) 0 (0.0)
Oral residue (0-4) 19 15 0.26
Complete clearance 0 (0.0) 0 (0.0)
Trace residue 0 (0.0) 2 (13.3)
Residue collection 18 (94.7) 13 (86.7)
Majority bolus remaining 0 (0.0) 0 (0.0)
Minimal/no clearance 1 (5.3) 0 (0.0)
Pharyngeal residue (0-4) 21 17 0.35
Complete clearance 0 (0.0) 0 (0.0)
Trace residue 7 (33.3) 2 (11.8)
Residue collection 14 (66.7) 15 (88.2)
Majority bolus remaining 0 (0.0) 0 (0.0)
Minimal/no clearance 0 (0.0) 0 (0.0)
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dysphagia [25, 26]. It is also possible that the improvement in
PAS scores in both groups was due to a combination of spon-
taneous recovery and/or swallowing treatment (PES and/usual
SLT care). This is because, in the original STEPS trial, both
groups received usual SLT care, and in order to preserve blind-
ing as much as possible, both groups also received some PES to
obtain threshold and tolerance levels [7]. In addition, levels of
PES given to participants in the active group may have been at
suboptimal levels, so-called “undertreatment” [7] which may
account for why no treatment effect was evident in the STEPS
trial and in this research.
We chose the mode bolus as the primary method of anal-
ysis as it represents the most frequently occurring swallow
pattern across a series of swallows. It therefore may be a more
instructive way to measure PAS scores, being more represen-
tative of a patient’s unique swallow pattern, as opposed to the
mean or median [6]. Improvements in the mode bolus there-
fore may be important. Choosing different boli to analyse
may also help to inform methods in evaluating the PAS. It
is well known that in acute stroke, there is high intrasubject
variability of PAS scores, observed both in this study and doc-
umented previously [4–7, 24] with some patients showing a
worse or better pattern of swallows even across the same bolus
[6, 24] and between boli. This makes the task of predicting
aspiration challenging [27] and presents challenges for
researchers when considering which boli to analyse and how.
Future studies with more participants will provide more infor-
mation either way, both for clinicians and researchers alike.
As with PAS scores, in the acute phase of stroke, one
would expect a trend for longitudinal improvements in tim-
ings as patients recover [9, 23]. This was also observed in this
study and, like the PAS scores, may have been due to a com-
bination of spontaneous recovery and/or usual SLT care
and/or PES. The significant change seen in STD alone could
be due to increased numbers available for that measure (55)
compared to less numbers for OTT (29), ILC (49), and PTT
(25). Two-timing measures (LVCrt and PRT) and both dura-
tion measures (UOSD and LCD) did not show a trend for
improvement. Due to the modest sample size, it is too early
to draw any conclusions from these data at present.
No significant results were seen between the groups for
the worst 50ml bolus. Few studies have reported on swallow-
ing larger boli (≥50ml) in acute stroke patients, perhaps due
to concerns regarding safety and one study that did evaluate
swallowing of 100ml of thin barium only included milder
patients [28]. No studies involving PES have included a
50ml bolus, apart from the STEPS study. In the current
study, although the 50ml bolus was swallowed using multiple
swallows, it was viewed as one swallowing task (participants
were effectively asked to swallow the bolus “in one go”).
Hence, the highest (worst) PAS score from this task was
chosen to be analysed. This was different to the 5ml boli
which were six separate, discrete swallowing tasks where a
mode could be clearly extracted from across the series.
The numerous measures performed in this research rep-
resent a comprehensive analysis of swallow safety, timings,
and clearance. The findings from this study suggest that
including timings and clearance measures did not result in
the detection of differences in swallow function that may
have been missed using the PAS scale alone. Equally, in the
numbers studied, it is probable that there was no effect to be
detected, and hence, it is premature to conclude that only
using the PAS is enough to capture change in swallowing func-
tion following an intervention. The main reason for lower
numbers was due to reduced imaging quality and suboptimal
frame rate in the final analysis. This has highlighted the
importance of acquiring images at the correct frame rate and
optimising data quality and field of view as much as possible.
This study has several strengths. These include analysis of
a large dataset with deep phenotypic information from a
high-fidelity phase III trial that followed a published proto-
col; a comprehensive analysis which encompasses all aspects
of the swallow (safety, speed, duration, and efficiency) and is,
to our knowledge, the first study to publish results of stroke
patients focusing on the PAS scores from the mode swallow.
However, some limitations are present. As this real-life
study included VFSS from 18 different hospitals in 5 coun-
tries inevitably, some images were of suboptimal quality,
resulting in missing data as image quality was not good
enough to allow measurements or were out of field of view.
VFSS frame rates also varied both within and between sites
which also reduced the number of files available for analysis.
In addition, one site contributed significantly more data than
other sites which may represent a bias within the results.
In summary, including measures of timing and clearance
(in addition to safety measures) did not detect any further
changes in swallowing function. Adequately powered studies,
assessing the effect of PES in the acute stroke where PES is
given solely to the PES group and at the optimal dose
(preventing “undertreatment”), are required.
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